What does CJC-1295 research tell us about children?
Very little. The published human CJC-1295 studies discussed here involved adults. They don’t establish a treatment for children or support giving them the CJC-1295 and ipamorelin combination.
The FDA’s CJC-1295 review found no studies showing that it treats growth hormone deficiency, meaning a shortage of that hormone. It also notes that people with complete deficiency won’t respond to these hormone-release signals.
Sermorelin’s childhood growth study concerns a different substance and children with a diagnosed shortage. Its findings don’t transfer to CJC-1295. A concern about a child’s growth belongs in clinical care, where the cause can be assessed.
Is “no DAC” just a small naming difference?
No. DAC means drug affinity complex: an attachment that binds CJC-1295 to albumin, a blood protein, helping it last longer. The form without that attachment is a different substance.
The FDA review distinguishes the forms and found no human studies of CJC-1295 without DAC. A timing claim about one form doesn’t establish what happens with the other. Our CJC-1295 and ipamorelin page explains the distinction.
Does a certificate show that a peptide works?
A certificate of analysis reports tests on a sample. It isn’t a clinical trial and can’t show a health benefit. A purity figure doesn’t settle whether the sample has the right identity or is sterile, meaning free of living microbes.
We don’t authenticate certificates or products. The sample, the test method and the actual report all matter. Even accurate paperwork leaves the human benefit question open.
Has MOTS-c replaced exercise in a human trial?
The exercise paper measured people’s natural MOTS-c and gave the peptide to mice. The performance results belong to mice.
A registered human study concerns insulin sensitivity, how well the body responds to insulin, in adults with prediabetes and extra weight. Its registry record had no results as of September 30, 2026. A study plan doesn’t establish benefits or safety, and it isn’t a trial of replacing exercise.
Do FDA records settle Australian access?
No. They concern the United States. They don’t establish Australian prescribing permission, classification or availability.
And compounded drugs aren’t FDA-approved, even when prescribed. The comparison explains the separate compounding entries and why a withdrawn nomination isn’t permission to compound.